Controversies in metastatic prostate cancer

**Aims and objectives of this session**
This session will summarise most recent developments in castration sensitive and castration resistant metastatic prostate cancer. In particular, surgical resection of oligometastatic disease, new biomarkers and targets are to be discussed as part of individualised patient care. Furthermore, the upcoming role of immunotherapy in prostate cancer will be presented.

10:30 - 10:50 **Debate** *Is there a role for local treatment of oligometastatic disease?*

- **Yes**
  - M. Spahn, Berne (CH)

- **No**
  - B. Tombal, Brussels (BE)

10:50 - 11:05 **State-of-the-art lecture** *EAU Guidelines on mCRPC - An update*
  - P. Cornford, Liverpool (GB)

11:05 - 11:07 **Introduction** *Society for Urologic Oncology (SUO)*
  - C.R. Chapple, Sheffield (GB)

11:07 - 11:20 **Society for Urologic Oncology (SUO) lecture** *Current and future biomarkers in castration resistant prostate cancer*
  - C.P. Evans, Sacramento (US)

11:20 - 11:35 **State-of-the-art lecture** *Next generation targets for individualised treatment*
  - J. De Bono, Sutton (GB)

11:35 - 12:00 **Associated abstract presentation**
  - 748
    - **Targeting androgen receptor variants by niclosamide overcomes resistance to abiraterone and enzalutamide**
      - By: Liu C., Lou W., Pan C-X., Evans C., Gao A
      - **Institutes:** University of California Davis, Dept. of Urology, Sacramento, United States of America

**State-of-the-art lecture**